Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.

PURPOSE In approximately 20% of patients with superficial bladder tumors, the tumors progress to invasive tumors after treatment. Current methods of predicting the clinical behavior of these tumors prospectively are unreliable. We aim to identify a molecular signature that can reliably identify patients with high-risk superficial tumors that are likely to progress to invasive tumors. PATIENTS AND METHODS Gene expression data were collected from tumor specimens from 165 patients with bladder cancer. Various statistical methods, including leave-one-out cross-validation methods, were applied to identify a gene expression signature that could predict the likelihood of progression to invasive tumors and to test the robustness of the expression signature in an independent cohort. The robustness of the gene expression signature was validated in an independent (n = 353) cohort. RESULTS Supervised analysis of gene expression data revealed a gene expression signature that is strongly associated with invasive bladder tumors. A molecular classifier based on this gene expression signature correctly predicted the likelihood of progression of superficial tumor to invasive tumor. CONCLUSION We present a molecular signature that can predict, at diagnosis, the likelihood of bladder cancer progression and, possibly, lead to improvements in patient therapy.

[1]  S. Dudoit,et al.  Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data , 2002 .

[2]  J. Nevins,et al.  The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.

[3]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Sang Eun Lee,et al.  Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor. , 2004, Urology.

[5]  J. Seigne,et al.  Characteristics of invasive bladder cancers: histological and molecular markers. , 1996, Seminars in urologic oncology.

[6]  Michael W Kattan,et al.  Evaluating a New Marker’s Predictive Contribution , 2004, Clinical Cancer Research.

[7]  Anne-Mette K. Hein,et al.  Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study , 2007, Clinical Cancer Research.

[8]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[9]  V. Arango,et al.  Using the Gene Ontology for Microarray Data Mining: A Comparison of Methods and Application to Age Effects in Human Prefrontal Cortex , 2004, Neurochemical Research.

[10]  Yingdong Zhao,et al.  Analysis of Gene Expression Data Using BRB-Array Tools , 2007, Cancer informatics.

[11]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[12]  S. Johansson,et al.  Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. , 2002, The Journal of urology.

[13]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[14]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Steinberg Gd,et al.  Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. , 1992 .

[16]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[17]  S. Thorgeirsson,et al.  Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.

[18]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[19]  J. Pow-Sang,et al.  Contemporary management of superficial bladder cancer. , 2000, Cancer control : journal of the Moffitt Cancer Center.

[20]  Richard Simon,et al.  A random variance model for detection of differential gene expression in small microarray experiments , 2003, Bioinform..

[21]  Sang-Bae Kim,et al.  GAzer: gene set analyzer , 2007, Bioinform..

[22]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[23]  N. Dyson,et al.  A revised picture of the E2F transcriptional network and RB function. , 2002, Current opinion in cell biology.

[24]  M. Knowles,et al.  Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. , 1991, Oncogene.

[25]  Richard M. Simon,et al.  A Paradigm for Class Prediction Using Gene Expression Profiles , 2003, J. Comput. Biol..

[26]  C. Busch,et al.  Recurrence and progression in low grade papillary urothelial tumors. , 1999, The Journal of urology.

[27]  H. Herr,et al.  Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. , 1997, British journal of urology.

[28]  S. Groshen,et al.  Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. , 1998, Cancer research.

[29]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[30]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[31]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[32]  Carlos Cordon-Cardo,et al.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[34]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[35]  S. Thorgeirsson,et al.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.

[36]  R. Millikan,et al.  Focus on bladder cancer. , 2004, Cancer cell.

[37]  Michael W Kattan,et al.  Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.

[38]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[39]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.